Next, we further investigated the potential of the LDLR-targeting conjugate for use as a clinical tool aiming to specifically target stroma-rich PDAC rather than pancreatic diseases, such as mass-forming chronic pancreatitis (CP). Here, LDLR is linked to chronic pancreatitis.